Pharmaceuticals, Biotechnology & Life Sciences

Short‑interest rises at WuXi AppTec, yet robust backlog, pipeline, and AI‑driven margin‑boosting plans keep its outlook strong.

Goldman Sachs lifts Roche Holding to neutral, citing stronger diagnostics-driven pricing and solid balance sheet amid looming patent cliffs – a fresh outlook for investors.

Swedish Orphan Biovitrum’s Aspaveli gains EU approval, boosting sales guidance and brokerage upside as the company expands its rare‑kidney drug portfolio.

European Commission approves Sandoz’s Ondibta, a biosimilar insulin, promising lower costs, wider access, and new competition in the EU insulin market.

Discover how Natera’s new AI‑driven MRD platform could change oncology care—boosting early relapse detection and tailoring treatment at JHC 2024.

West Pharmaceutical Services: how WPS capitalizes on drug‑delivery tech, ESG trends, and digital twins to stay ahead of EU MDR, competition, and supply‑chain risks.

United Therapeutics updates at JHC: focus on prostacyclin PAH therapies, value‑based contracts, patent strategy, and potential M&A for growth.

Fosun Pharma’s new Jinan Fund stake transfer and drug registration approval signal strategic growth, boosting investor confidence in its innovation‑driven portfolio.

Lonza Group AG boosts investor interest with a robust biologics focus, partnership strategy, and strong financials, positioning it for growth in the Swiss market.

Regeneron’s strategy: hearing‑loss gene‑therapy and weight‑loss drugs aimed at new growth, backed by strong cash flow and disciplined M&A, to offset patent cliffs and boost 2030 revenues.